Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.
Burchert A, Saussele S, Eigendorff E, Müller MC, Sohlbach K, Inselmann S, Schütz C, Metzelder SK, Ziermann J, Kostrewa P, Hoffmann J, Hehlmann R, Neubauer A, Hochhaus A.
Burchert A, et al. Among authors: hoffmann j.
Leukemia. 2015 Jun;29(6):1331-5. doi: 10.1038/leu.2015.45. Epub 2015 Feb 25.
Leukemia. 2015.
PMID: 25712735